The first affiliated hospital of Xinjiang medical university

Ürümqi 830054

2 studies enrolling now · 6 studies all time

What they study most

Atherosclerotic Cardiovascular Disease (ASCVD), Depressive Disorder, Treatment-Resistant, Elevated Lp(a), Ischemic Stroke; Ischemic Attack, Transient, Kidney Disease, Chronic, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Primary Biliary Cholangitis

Studies at this site

• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) — Recruiting now
• Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis — Recruiting now
• A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE — Running, not enrolling
• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) — Running, not enrolling
• A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression — Completed
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer — Running, not enrolling